Your Messages Inbox
Your Article Summary
See Latest ArticlesCryoLife Receives FDA 510 Clearance for SynerGraft Processed Human Cardiac Patch Material
Cryolife, 08/13/09
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced that it has received 510 clearance from the U.S. Food and Drug Administration (FDA) for its CryoPatch SG pulmonary human cardiac patch. CryoPatch SG is processed with the Company's proprietary SynerGraft technology designed to remove allogeneic donor cells and cellular remnants from tissue without compromising the integrity of the underlying collagen matrix.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Sanofi Pasteur obtains license from Syntiron to develop & commercialize vaccine to prevent Staphylococcus infections
Sanofi-aventis, 12/17/09
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Article Search
Sponsor